Shrinidhi Nathany: New ASCO 2026 ctDNA Clinical Practice Guideline
9h agoen
From the article
Shrinidhi Nathany, Consultant Molecular Hematology and Oncology at Fortis Memorial Research Institute, India, shared a post on LinkedIn: “New guideline alert – ASCO 2026, Circulating tumor DNA (ctDNA) has rapidly moved […]
Continue reading on OncoDailyYou might also wanna read
Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy
doi.org·1d ago
Timing of ctDNA Testing in HR+/HER2- Advanced Breast Cancer
clinicaltrials.gov·1d ago
ctDNA-Guided Intraventricular Therapy for CNS Malignancies
clinicaltrials.gov·1d ago
ctDNA Assessment in Endometrial Cancer for Adjuvant Therapy
clinicaltrials.gov·7d ago
New workflow tool gives scientists a clearer view of how DNA is regulated
Phys·3d ago
A Multicenter Randomized Open-Label Trial Evaluating MRD-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
clinicaltrials.gov·1d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.